Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone dipropionate) in ...

Chronic Lower Back Pain (CLBP) market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis ...

MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney ...

Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, ...

Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Sukuru had technical oversight of more than a dozen contract development and manufacturing organizations worldwide while working at Endo Pharma. In his current role at Catalent, he works with hundreds ...